Inhibrx Biosciences (INBX) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$2.34

Estimate

-$2.28

Surprise

-2.6%

Score today

4.8/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Inhibrx Biosciences (INBX) reported a wider loss than forecast — diluted EPS of -$2.34 against the -$2.28 estimate (a 2.6% shortfall).

• Inhibrx Biosciences Q2 EPS $(2.34) Beats $(2.39) Estimate — benzinga, 2026-08-13

TrendMatrix currently rates INBX Sell at 4.8/10; no pre/post engine snapshot brackets this report.

0 of the last 4 quarters beat the estimate; this quarter's -2.6% surprise compares with a -28.9% four-quarter average. Next scheduled report: 2026-11-13.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$123.00

Price target

$226.67

Stop

$112.69

Upside to target

+84.3%

Reward-to-risk

5.8:1

Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.78B

P/E (fwd)

-13.8

52-week range

$26.19–$155.29

Off 52-week high

20.8%

RSI (14)

80

Volume vs avg

0.70×

Score today

4.8/10